320
Participants
Start Date
July 31, 2017
Primary Completion Date
April 2, 2020
Study Completion Date
August 3, 2020
RBX2660
RBX2660 is a rectally administered microbiota suspension
Placebo
Placebo is normal saline solution administered rectally
Open label RBX2660 (only for confirmed CDI recurrence)
RBX2660 administered as a second treatment after confirmed CDI recurrence following the initial dose of placebo or RBX2660
New York, New York
North Massapequa, North Massapequa
Rochester, Rochester
Uniontown, Uniontown
Flourtown, Flourtown
Philadelphia, Philadelphia
Wyomissing, Wyomissing
Springfield, Springfield
Winchester, Winchester
Durham, Durham
Greenville, Greenville
Wilmington, Wilmington
Charleston, Charleston
Atlanta, Atlanta
Atlanta, Atlanta
Port Orange, Port Orange
Jacksonville, Jacksonville
Gainesville, Gainesville
Miami, Miami
Athens, Athens
Dothan, Dothan
Hixson, Hixson
Lexington, Lexington
Toledo, Toledo
Lafayette, Lafayette
Detroit, Detroit
Madison, Madison
Marshfield, Marshfield
Plymouth, Plymouth
Rochester, Rochester
Rapid City, Rapid City
Fargo, Fargo
Gurnee, Gurnee
Highland Park, Highland Park
Maywood, Maywood
St. Louis, St Louis
Topeka, Topeka
Wichita, Wichita
Omaha, Omaha
New Orleans, New Orleans
Shreveport, Shreveport
North Little Rock, North Little Rock
Dallas, Dallas
Houston, Houston
Aurora, Aurora
Idaho Falls, Idaho Falls
West Jordan, West Jordan
Phoenix, Phoenix
Las Vegas, Las Vegas
Los Angeles, Los Angeles
Oxnard, Oxnard
Lancaster, Lancaster
Sacramento, Sacramento
Portland, Portland
Seattle, Seattle
Hamden, Hamden
Boston, Boston
Omaha, Omaha
Teaneck, Teaneck
Philadelphia, Philadelphia
Calgary, Calgary
Edmonton, Edmonton
Vancouver, Vancouver
Victoria, Victoria
Fredericton, Fredericton
Moncton, Moncton
Rebiotix Inc.
INDUSTRY